Latest Strategy Changes News

Aguia Resources has implemented strategic operational changes at its Santa Barbara Gold Project in Colombia, achieving a 70% gold recovery rate in December and targeting over 80% in early 2026.

Globe Metals & Mining has issued over 56 million shares to Director Bo Tan, settling nearly all of an outstanding loan and achieving a fully debt-free status. This financial milestone positions the company strongly for advancing its Kanyika Niobium Project.

Renascor Resources has completed major equipment installation and begun commissioning at its Australian Government co-funded Purified Spherical Graphite demonstration facility, marking a pivotal step in its sustainable battery anode materials strategy.

Caravel Minerals reports substantial progress on its Definitive Feasibility Study for the Caravel Copper Project, advancing engineering, environmental approvals, and strategic partnerships toward development.

Riversgold has signed key Native Title agreements and a funding partnership to advance its Northern Zone Gold Project near Kalgoorlie, aiming for production in 2026.

Structural Monitoring Systems Plc has removed director Ross Love following a Federal Court decision denying an injunction sought by Love and his associated company. The company continues to face ongoing legal proceedings amid serious workplace allegations.

Latrobe Magnesium Limited has received a $6.29 million R&D tax rebate from the ATO, using the funds to reduce debt and progress its magnesium production plants in Australia and Malaysia.

Chimeric Therapeutics has raised $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 trial through Phase 1, while initiating a strategic reset to sharpen focus and reduce costs.

Metgasco has pushed back the deadline for Vintage Energy’s commitment to acquire its stake in the Odin and Vali Gas Fields, extending the timeline while keeping the overall transaction completion date intact.

Carnegie Clean Energy’s Spanish subsidiary has sold its 2025 Basque R&D tax deductions for €773,163, securing immediate funding to advance its ocean wave energy technology under the ACHIEVE Programme.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Elevate Uranium has expanded its global uranium resource base to 169 million pounds of U3O8 through the strategic acquisition of the Napperby Uranium Project and complementary assets from Core Lithium. This move consolidates its Central Australian portfolio and leverages its proprietary U-pgrade™ beneficiation technology.